Oic Pamora denied as experimental or investigational by Humana?

Humana's specific coverage criteria for oic pamora are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny a PAMORA for OIC as Experimental

Peripherally acting mu-opioid receptor antagonists (PAMORAs) are FDA-approved agents specifically indicated for opioid-induced constipation (OIC). An "experimental" or "investigational" denial from Humana in this context is almost always an error in one of two forms: (1) an administrative miscoding where the claim was processed under an incorrect drug code or indication, or (2) an outdated internal policy that has not been updated to reflect current FDA approval status. In rare cases it reflects a request for an off-label use that the insurer has not recognized.

If your prescriber is using a PAMORA for its FDA-approved OIC indication, an experimental denial is factually incorrect and highly contestable.

## Why This Denial Is Appealable

• Internal appeal (ERISA §503 / ACA §2719): A denial based on experimental status when the drug carries FDA approval for the prescribed indication is a factual error. File a written appeal with regulatory documentation. Plans must conduct a full-and-fair review.
• External review (ACA §2719): After internal exhaustion, or at 4 months from the denial date, an Independent Review Organization reviews the clinical and regulatory record. The IRO's decision is binding on the plan.
• Expedited review: Available when standard timelines would seriously jeopardize your health.

## Documentation to Gather

1. FDA prescribing label: Print the current FDA-approved prescribing information for the specific PAMORA prescribed from DailyMed (dailymed.nlm.nih.gov). The label will show the approved indication for OIC. Highlight the indication language. 2. FDA approval history: The FDA approval date is publicly available; note it in your appeal letter to establish that the drug is not investigational. 3. Diagnosis and indication match: Chart notes and ICD-10 diagnosis codes from your prescriber confirming that the prescribed use is exactly the FDA-approved indication. 4. Claim coding verification: Ask your prescriber's billing office to confirm that the NDC, HCPCS code, and diagnosis codes submitted are accurate and reflect the approved indication. 5. Prescriber letter: A brief letter from your physician confirming the on-label basis for prescribing.

## Criteria-Mapping Structure

In your appeal letter, make the regulatory argument first and clearly: "[Drug name] received FDA approval for opioid-induced constipation in adults on chronic opioid therapy. The prescribed use is exactly the approved indication. The plan's characterization of this drug as experimental or investigational is factually incorrect under current FDA status." Attach the FDA label as Exhibit A. Keep the argument focused — a narrow, documented factual correction is more effective than a broad clinical argument when the denial rests on regulatory status.

## Next Step

Call Humana Member Services before filing a written appeal. Provide the FDA approval date and ask whether the denial can be reversed administratively. Document the call (date, representative name, reference number). If not resolved by phone, escalate to a formal written appeal with the FDA label attached.